This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 161-165, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.161-165.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Ken B. Waites,1,2* Donna M. Crabb,2 Xue Bing,2 and Lynn B. Duffy2

Departments of Pathology,1 Microbiology, University of Alabama at Birmingham, Birmingham, Alabama2

Received 3 June 2002/ Returned for modification 19 September 2002/ Accepted 8 October 2002

The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 Mycoplasma pneumoniae, 45 Mycoplasma hominis, 15 Mycoplasma fermentans, and 68 Ureaplasma sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at <=1 µg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC90s; <=0.008 µg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae. For M. hominis, the garenoxacin MIC90 (<=0.008 µg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 M. fermentans isolates were inhibited by garenoxacin at concentrations <=0.008 µg/ml, making it the most active drug tested against this organism. For Ureaplasma spp., the garenoxacin MIC90 (0.25 µg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against M. pneumoniae and M. hominis by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

* Corresponding author. Mailing address: Department of Pathology, WP 230, University of Alabama, 619 19th St., South Birmingham, AL 35249. Phone: (205) 934-4960. Fax: (205) 975-4468. E-mail: waites{at}path.uab.edu.

Antimicrobial Agents and Chemotherapy, January 2003, p. 161-165, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.161-165.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2008). Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 52: 3776-3778 [Abstract] [Full Text]  
  • Yamazaki, T., Sasaki, T., Takahata, M. (2007). Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 51: 2278-2279 [Full Text]  
  • Hamasuna, R., Osada, Y., Jensen, J. S. (2005). Antibiotic Susceptibility Testing of Mycoplasma genitalium by TaqMan 5' Nuclease Real-Time PCR. Antimicrob. Agents Chemother. 49: 4993-4998 [Abstract] [Full Text]  
  • Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D. (2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 4128-4136 [Abstract] [Full Text]  
  • Waites, K. B., Reddy, N. B., Crabb, D. M., Duffy, L. B. (2005). Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 49: 2541-2542 [Abstract] [Full Text]  
  • Waites, K. B., Talkington, D. F. (2004). Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clin. Microbiol. Rev. 17: 697-728 [Abstract] [Full Text]  
  • Pereyre, S., Renaudin, H., Bebear, C., Bebear, C. M. (2004). In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas. Antimicrob. Agents Chemother. 48: 3165-3168 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 3973-3975 [Abstract] [Full Text]  
  • Duffy, L. B., Crabb, D. M., Bing, X., Waites, K. B. (2003). Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 52: 527-528 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»